Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma, but even after successful initial treatment, a significant hurdle remains. Up to 60% of patients experience relapse within the first two years of remission. This recurrence can be devastating, with limited treatment options and a significant drop in survival rates.
Glofitamab (Columvi, Roche) is a bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. It redirects a patient’s T cells to eliminate malignant B cells.
Side effects may include:
Glofitamab is being investigated alone and in combination with other medicines, including polatuzumab vedotin (Polivy), in earlier lines of treatment for people with B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and other blood cancers.
In April 2024, the manufacturer announced that the phase III study STARGLO has shown that patients with relapsed or refractory DLBCL treated with glofitamab with standard chemotherapy (GemOx; gemcitabine and oxaliplatin) live significantly longer than those treated with rituximab and GemOx.
This study included relapsed or refractory patients who had received one previous line of treatment and were not eligible for a stem cell transplant. The sponsor will release more data in an upcoming medical conference.
Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of all cases. DLBCL is a fast-growing and aggressive form of NHL that responds well to treatment in the initial stages. However, many individuals suffer from relapse or refractory disease, which limits their options for salvage therapy and results in poor survival rates. Enhancing treatments during the early stages of the disease and offering alternative options can aid in improving long-term outcomes.
Stay updated with HealthTree for DLBCL on the latest treatment advances:
Sources:
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma, but even after successful initial treatment, a significant hurdle remains. Up to 60% of patients experience relapse within the first two years of remission. This recurrence can be devastating, with limited treatment options and a significant drop in survival rates.
Glofitamab (Columvi, Roche) is a bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. It redirects a patient’s T cells to eliminate malignant B cells.
Side effects may include:
Glofitamab is being investigated alone and in combination with other medicines, including polatuzumab vedotin (Polivy), in earlier lines of treatment for people with B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and other blood cancers.
In April 2024, the manufacturer announced that the phase III study STARGLO has shown that patients with relapsed or refractory DLBCL treated with glofitamab with standard chemotherapy (GemOx; gemcitabine and oxaliplatin) live significantly longer than those treated with rituximab and GemOx.
This study included relapsed or refractory patients who had received one previous line of treatment and were not eligible for a stem cell transplant. The sponsor will release more data in an upcoming medical conference.
Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of all cases. DLBCL is a fast-growing and aggressive form of NHL that responds well to treatment in the initial stages. However, many individuals suffer from relapse or refractory disease, which limits their options for salvage therapy and results in poor survival rates. Enhancing treatments during the early stages of the disease and offering alternative options can aid in improving long-term outcomes.
Stay updated with HealthTree for DLBCL on the latest treatment advances:
Sources:
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.